ClinicalTrialsFinder
RecruitingNCT06690983

Tau PET/CT in Various Tau-Related Disease Patients

Sponsor

Tianjin Medical University

Enrollment

500 participants

Start Date

Aug 1, 2018

Study Type

OBSERVATIONAL

Conditions

Neurodegenerative DiseasesNeurodegenerationTauopathies

Summary

To evaluate the potential usefulness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria1

  • \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria1

  • \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST18F-S16/T807

Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.

Locations(2)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06690983

Related Trials

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

NCT063039213 locations

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

NCT075454731 location

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCT072244901 location

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789141 locations

Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)

NCT053546221 location